JP4476807B2 - ポリ（カリウムおよびスチレンスルホン酸ナトリウム）、その製造およびその使用 - Google Patents

ポリ（カリウムおよびスチレンスルホン酸ナトリウム）、その製造およびその使用 Download PDF

Info

Publication number
JP4476807B2
JP4476807B2 JP2004523573A JP2004523573A JP4476807B2 JP 4476807 B2 JP4476807 B2 JP 4476807B2 JP 2004523573 A JP2004523573 A JP 2004523573A JP 2004523573 A JP2004523573 A JP 2004523573A JP 4476807 B2 JP4476807 B2 JP 4476807B2
Authority
JP
Japan
Prior art keywords
potassium
sodium
copolymer
solution
polystyrene sulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004523573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502249A (ja
JP2006502249A5 (https=
Inventor
マスカー，スニル，ブイ．
バガット，ヒテシュ，アール．
カーツ，キャロライン，アイ．
カッティ，サンジーブ，エス．
チャンセラー−アダムス，トーニ，ジー．
コルゲーデ，ムクンド，エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2006502249A publication Critical patent/JP2006502249A/ja
Publication of JP2006502249A5 publication Critical patent/JP2006502249A5/ja
Application granted granted Critical
Publication of JP4476807B2 publication Critical patent/JP4476807B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F12/02—Monomers containing only one unsaturated aliphatic radical
    • C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
    • C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
    • C08F12/30—Sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/44—Preparation of metal salts or ammonium salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L25/00—Compositions of, homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Compositions of derivatives of such polymers
    • C08L25/18—Homopolymers or copolymers of aromatic monomers containing elements other than carbon and hydrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
JP2004523573A 2002-07-22 2003-07-18 ポリ（カリウムおよびスチレンスルホン酸ナトリウム）、その製造およびその使用 Expired - Lifetime JP4476807B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39786802P 2002-07-22 2002-07-22
PCT/US2003/022514 WO2004009100A1 (en) 2002-07-22 2003-07-18 Poly (potassium and sodium styrene sulfonate), its manufacture and its uses

Publications (3)

Publication Number Publication Date
JP2006502249A JP2006502249A (ja) 2006-01-19
JP2006502249A5 JP2006502249A5 (https=) 2006-07-13
JP4476807B2 true JP4476807B2 (ja) 2010-06-09

Family

ID=30771134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004523573A Expired - Lifetime JP4476807B2 (ja) 2002-07-22 2003-07-18 ポリ（カリウムおよびスチレンスルホン酸ナトリウム）、その製造およびその使用

Country Status (11)

Country Link
US (4) US20050214246A1 (https=)
EP (1) EP1542706A1 (https=)
JP (1) JP4476807B2 (https=)
KR (1) KR20050030208A (https=)
CN (3) CN101081230A (https=)
AU (1) AU2003254007B2 (https=)
BR (1) BR0312884A (https=)
CA (1) CA2492211A1 (https=)
MX (1) MXPA05000687A (https=)
NZ (1) NZ537594A (https=)
WO (1) WO2004009100A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951853B2 (en) * 2002-05-02 2011-05-31 Smart Anti-Microbial Solutions, Llc Polymer-based antimicrobial agents, methods of making said agents, and products incorporating said agents
EP1542706A1 (en) * 2002-07-22 2005-06-22 Genzyme Corporation Poly (potassium and sodium styrene sulfonate), its manufacture and its uses
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
AU2005295708A1 (en) * 2004-10-13 2006-04-27 Relypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
US20120135060A1 (en) * 2005-11-02 2012-05-31 Shmuel Bukshpan Compositions and methods for cell killing
JP5253175B2 (ja) 2005-11-14 2013-07-31 ヴァロリサシオン−ルシェルシュ・リミテッド・パートナーシップ 非加水分解共有結合を有するポリマー性バインダーを含む医薬組成物およびセリアック病の治療における使用
US7915235B2 (en) * 2006-03-20 2011-03-29 Brian Dieckgraefe High affinity ligands bind to clostridium difficile toxin A
TW200829286A (en) * 2006-09-06 2008-07-16 Genzyme Corp Polystyrene sulfonate polymer tablets, their preparation and use
JP5954798B2 (ja) * 2011-11-16 2016-07-20 東ソー有機化学株式会社 高純度パラスチレンスルホン酸（塩）、それを用いたポリスチレンスルホン酸（塩）、およびポリスチレンスルホン酸（塩）を用いた、分散剤、導電性ポリマードーパント、ナノカーボン材料水性分散体、導電性ポリマー水性分散体、ならびにポリスチレンスルホン酸（塩）の製造方法
KR102545700B1 (ko) * 2020-12-08 2023-06-21 동아대학교 산학협력단 폴리스티렌설폰산 금속염, 이의 제조방법 및 이를 포함하는 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224941A (en) * 1963-01-21 1965-12-21 Lilly Co Eli Resin compositions and method for controlling diarrhea
DE1480628C3 (de) * 1965-10-28 1975-02-06 Alfred 2000 Hamburg Wriedt Kupplung für einen Förderkarrenzug
US3466365A (en) * 1967-07-24 1969-09-09 White Lab Inc Antiviral compositions and method of use
US3987163A (en) * 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
IE44690B1 (en) * 1976-02-04 1982-02-24 Rohm & Haas Pharmaceutical compositions containing polyvinylbenzenosulfonic acids
US4395392A (en) * 1980-06-24 1983-07-26 Adria Laboratories Inc. Method for treating kidney stones
US4362711A (en) * 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
US5171738A (en) * 1982-10-04 1992-12-15 Toray Industries, Inc. Method of treating malignant tumors
US5435821A (en) * 1985-12-12 1995-07-25 Exxon Research & Engineering Co. Controlled release vegetation enhancement agents coated with sulfonated polymers, method of production and prcesses of use
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
JPH0219319A (ja) * 1988-05-26 1990-01-23 Duphar Internatl Res Bv ラクツロースシロップから単離したフラクション及びこれを有効成分とする抗内毒素作用を有する医薬組成物
US5149523A (en) * 1989-06-20 1992-09-22 Aktiebolaget Hassle Polystyrenesulfonate-drug complex and solid dosage forms thereof
US5093130A (en) * 1989-09-26 1992-03-03 Plant Genetics Powder coated hydrogel capsules
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5277820A (en) * 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5614559A (en) * 1993-11-23 1997-03-25 Procept Inc. Compound for inhibiting HIV infectivity
US5484773A (en) * 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
WO1995024186A1 (en) * 1994-03-11 1995-09-14 Pharmacopeia, Inc. Sulfonamide derivatives and their use
WO1996007430A1 (en) * 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
EP0704697A1 (en) * 1994-09-27 1996-04-03 General Motors Corporation Exhaust sensor including a ceramic tube in metal tube package
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
DE19515554C2 (de) * 1995-04-27 1999-06-17 Braun Melsungen Ag Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma
US6034129A (en) * 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
US5800803A (en) * 1997-02-10 1998-09-01 Colgate-Palmolive Company Oral composition exhibiting enhanced uptake by dental tissue of noncationic antibacterial agents
US6521257B1 (en) * 1997-06-20 2003-02-18 Ohkura Pharmaceutical Co., Ltd. Gelled compositions
US6290947B1 (en) * 1997-09-19 2001-09-18 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin-binding agents
US6060235A (en) * 1997-09-19 2000-05-09 Geltex Pharmaceuticals, Inc. Antiviral polymers comprising acid functional groups and hydrophobic groups
US6007803A (en) * 1997-09-19 1999-12-28 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin binding agents
WO1999020285A1 (en) * 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Gel preparations containing polystyrenesulfonate
US6221248B1 (en) * 1998-03-23 2001-04-24 Ionics Incorporated Styrene sulfonate cation exchange membrane
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6270755B1 (en) * 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6290946B1 (en) * 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
CA2314494A1 (en) * 2000-05-02 2001-11-02 Geltex Pharmaceuticals, Inc. Anionic polymers as species specific antibacterial agents
US6537538B2 (en) * 2000-12-18 2003-03-25 Rush-Presbyterian-St. Luke's Medical Center Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
EP1542706A1 (en) * 2002-07-22 2005-06-22 Genzyme Corporation Poly (potassium and sodium styrene sulfonate), its manufacture and its uses
KR100714648B1 (ko) * 2005-12-02 2007-05-07 삼성전자주식회사 인쇄 회로 기판

Also Published As

Publication number Publication date
CA2492211A1 (en) 2004-01-29
WO2004009100A1 (en) 2004-01-29
NZ537594A (en) 2008-05-30
CN101081230A (zh) 2007-12-05
CN1671401A (zh) 2005-09-21
US20070053864A1 (en) 2007-03-08
US20090175818A1 (en) 2009-07-09
JP2006502249A (ja) 2006-01-19
MXPA05000687A (es) 2005-04-08
CN101319023A (zh) 2008-12-10
BR0312884A (pt) 2005-06-14
AU2003254007B2 (en) 2007-08-23
AU2003254007A1 (en) 2004-02-09
HK1082417A1 (en) 2006-06-09
KR20050030208A (ko) 2005-03-29
US20050214246A1 (en) 2005-09-29
US20070053865A1 (en) 2007-03-08
EP1542706A1 (en) 2005-06-22
CN100411625C (zh) 2008-08-20

Similar Documents

Publication Publication Date Title
US20090175818A1 (en) Poly(Potassium and Sodium Styrene Sulfonate) Its Manufacture and Its Uses
US3297664A (en) Calcium salts of lightly cross-linked ethylenically unsaturated carboxylic acids anddiethylenically unsaturated aliphatics
CN100435806C (zh) 作为毒素结合剂和抗菌试剂的阴离子聚合物
CN108283647A (zh) 甘露糖醛二酸的组合物
JP2001517632A (ja) 毒素結合剤としてのカチオン性ポリマー
US12318756B2 (en) Macromolecular compositions comprising indene-derivatives, preparation thereof, and use thereof
US7767768B2 (en) Crosslinked amine polymers
WO2001066606A1 (en) Crosslinked anion-exchange resin or salt thereof
US20020168333A1 (en) Method for improving vascular access in patients with vascular shunts
JPH0127045B2 (https=)
EP1831266B1 (en) Crosslinked amine polymers
CN116874613A (zh) 一种广谱高效的抗菌多肽aph143及其制备方法和应用
US10953078B2 (en) Treatment and/or prevention of sepsis
CN118005741B (zh) 一种抗菌多肽ap16a及其制备方法和应用
HK1082417B (en) Poly (potassium and sodium styrene sulfonate), its manufacture and its uses
US20030180381A1 (en) Use of metal compounds to treat gastrointestinal infections
JPH01316324A (ja) コレステロール低下剤
KR20150038026A (ko) 항박테리아 화합물의 나노입자 조성물 및 그의 다른 용도
CN103384523B (zh) 硝呋太尔在治疗由梭菌属物种所引起的感染中的用途
WO2013054148A1 (en) Use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of the haemolytic uremic syndrome
WO2024204698A1 (ja) 医薬組成物
EA041420B1 (ru) Композиции маннуроновой дикислоты, способы ее получения и использования
WO2020001643A1 (zh) 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100226

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100310

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3